The Pathology Core provides pathology and laboratory support for all SPORE projects including collection, prioritization, distribution and interrogation of both human prostate tissue and mouse models of prostate cancer (PCa). The Core collects and annotates diverse specimens, including fresh, frozen and formalin-fixed human tissue, biopsies including surveillance biopsies. The Core constructs tissue mircroarrays, processes whole mount and regular tissue blocks and tissue sections, and collects serum, plasma and urine for the analysis of DNA, RNA and protein. All specimens are collected at UCLA, Cedars-Sinai Medical Center (CSMC) and Greater LA VA Medical Center (GLA VA) in accordance with institutional guidelines and following established protocols with informed consent and patient confidentiality protected. Biospecimen repositories and data resources from the 3 sites are virtually integrated into a single unit. Through database infrastructure, collected bio-materials are linked to the clinical database at the parent institution and virtually integrated so that pathological, clinical, and family history data are available across institutions to maximize their potential use in translational research. Finally, the Pathology Core is responsible for prioritizing the access to all Core materials, with preference given to SPORE investigators. The Pathology Core is fully integrated with the Jonsson Cancer Center translational pathology core laboratory to avoid duplication of services and consolidate resources. Integrative services include enumeration and characterization of circulating tumor cells (CTCs) in a novel nanotechnology-based platform co-developed by the core, preparation of live epithelial cells from fresh human prostate tissue, laser-capture microdissection, digital pathology, quantitative immunohistochemistry (IHC) and immunofluorescence (IF) as well as multiplex immunohistochemistry. The core uses whole mount sections to correlate pathologic findings with imaging studies. Several specialized techniques to increase the knowledge gained from tissues are provided by the Core, such as multiplex immunohistochemical localization of proteins and RNA, laser capture microscopy, 3- dimensional visualization of cells in tissues through tissue clearing and light-sheet microscopy and computerized digital image analysis to quantify the cellular content and tissue architecture in pathology slides. In this context, the Pathology Core has the capacity to generate datasets from hematoxylin and eosin (H&E) and IHC/IF slides using whole slide digital scanning with machine learning and deep learning pipelines. The resulting data format is well suited for integration with other ?OMICS? data (i.e. genomics, proteomics, etc.). The large repertoire of available services is tailored to support each individual project or career development award. The Pathology Core has heavily invested in developing and acquiring new technologies to solve problems related to the procurement and analysis of all pathological specimens.

Public Health Relevance

The Pathology Core is integral to prostate cancer research at 3 institutions (UCLA, Cedars Sinai Medical Center, and Greater West Los Angeles-VA) in order to better diagnose and treat prostate cancer across all demographic groups. The Core is integrated with all SPORE projects and is responsible for collection, prioritization, distribution and interrogation of both human prostate tissue and mouse models of prostate cancer. All protocols are standardized across 3 institutions and SPORE sites are virtually connected, and the core is able to perform a menu of specialized innovative techniques for tissue analysis including digital image analysis and multiplex immunohistochemistry.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092131-16A1
Application #
9792322
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
16
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:
Navarro, Héctor I; Goldstein, Andrew S (2018) HoxB13 mediates AR-V7 activity in prostate cancer. Proc Natl Acad Sci U S A 115:6528-6529
Mitra, Mithun; Ho, Linda D; Coller, Hilary A (2018) An In Vitro Model of Cellular Quiescence in Primary Human Dermal Fibroblasts. Methods Mol Biol 1686:27-47
Li, Jiayun; Speier, William; Ho, King Chung et al. (2018) An EM-based semi-supervised deep learning approach for semantic segmentation of histopathological images from radical prostatectomies. Comput Med Imaging Graph 69:125-133
Kang, Jung J; Reiter, Robert E; Kummer, Nicolas et al. (2018) Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. Am J Clin Oncol 41:1-5
Lee, Ha Neul; Mitra, Mithun; Bosompra, Oye et al. (2018) RECK isoforms have opposing effects on cell migration. Mol Biol Cell 29:1825-1838
Aggarwal, Rahul; Huang, Jiaoti; Alumkal, Joshi J et al. (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503

Showing the most recent 10 out of 339 publications